Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

News Release

Groundwork BioAg and Sustainable Travel International Partner to Offer Carbon Dioxide Removal Credits for Tourism

Groundwork BioAg

Groundwork BioAg ®, the world’s largest producer of mycorrhizal inoculants, announced a new partnership with Sustainable Travel International, a global leader in sustainable tourism solutions, to offer travelers and businesses access to premium carbon dioxide removal (CDR) credits, based on the application of mycorrhizal fungi in cropland. Mycorrhizal inoculants are applied in agricultural soils to improve crop yields, save fertilizer, reduce plant stress, and improve soil health – but at the same time, these microbial products act as a natural pathway to permanently sequester carbon. This partnership aligns with Sustainable Travel International’s mission to provide programs that help travelers, businesses and destinations protect the environment, preserve cultural heritage and promote economic development. Groundwork BioAg's Rootella Carbon™ program offers high-integrity, high-volume, durable carbon credits that are independently certified and approved, providing a reliable solution for organizations seeking to meet their net-zero pledges responsibly. "By adding Rootella Carbon to our Climate Impact Portfolio, we reaffirm our commitment to promote holistic environmental stewardship so our members can visit – and protect – the places they love,” said Paloma Zapata, CEO of Sustainable Travel International. “This innovative, nature-based solution aligns with our mission to help the travel industry address its carbon liability while directly improving soil health around the world.” Sustainable Travel International’s Climate Impact Portfolio includes a wide variety of projects in different locations that generate carbon credits as they reduce or remove emissions. The portfolio includes a mix of high-quality forestry, clean/efficient energy, blue/teal carbon, and innovative climate tech projects. The demand for high-quality carbon credits is growing rapidly, with two-thirds of the world's largest companies with net-zero targets using carbon offsets to help meet their climate goals. Rootella Carbon credits stand out among durable CDR credits as a scalable solution that not only sequesters carbon in the soil but also improves crop yields, reduces chemical fertilizer use, mitigates plant stress and supports regenerative agricultural practices. Dan Grotsky, co-founder and chief growth officer of Groundwork BioAg, said, "This collaboration not only validates the effectiveness of our Rootella Carbon program but also demonstrates the travel industry's commitment to sustainable practices. Together, we are paving the way for significant carbon sequestration by enabling travelers and rewarding farmers around the world – while contributing to a healthier planet." Rooted in Groundwork BioAg’s history of helping growers improve the productivity and profitability of their farms, this partnership now gives travelers the opportunity to directly support farmers for their land stewardship while reducing their own carbon footprint. Currently under validation within the Verra VM0042 v2.0 protocol, Rootella Carbon offers farmers the opportunity to earn up to 70% of net proceeds from carbon credit sales, making it an attractive option for growers looking to diversify their income streams. This innovative approach unlocks compensation for regenerative growers who would otherwise be ineligible for carbon credits, while incentivizing conventional farmers to adopt regenerative practices. For more information about Groundwork BioAg and the Rootella Carbon program, visit GroundworkBioAg.com. About Groundwork BioAg Groundwork BioAg, a leading bioagriculture company, produces cost-effective mycorrhizal inoculants at scale to tackle food insecurity and climate change. Groundwork BioAg’s nature-based carbon dioxide removal solution leverages mycorrhizae as carbon’s main pathway into the soil and is supercharging permanent carbon sequestration on millions of hectares of commercial and regenerative farms globally. We envision the world’s cropland regenerating with mycorrhizae and every farmer benefiting from higher yields, healthier soils, fertilizer reduction, and verifiable, premium carbon credit revenue – without altering cultivation practices. Nature’s most potent carbon removal solution is now in every farmer’s hands. For more information, visit groundworkbioag.com or groundworkbioag.com/rootella-carbon. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

January 22, 2025 10:32 AM Central Standard Time

Cortland Biomedical Secures FDA Registration, Expanding Role as a Trusted Contract Manufacturer for Medical Device OEMs

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of global engineering, design, and manufacturing capabilities, is proud to announce its FDA registration, marking a significant milestone in the company’s evolution. This new designation positions Cortland Biomedical as a full-service contract manufacturer and reinforces the company’s unwavering commitment to delivering the highest standards of quality, compliance, and service to its medical device customers. As an FDA-registered contract manufacturer, Cortland Biomedical will better support its clients in highly regulated markets, particularly in the orthopedic sector, where precision and reliability are critical. The FDA registration, partnered with ISO 13486:2016 compliance, ensures that Cortland Biomedical operates under a robust Quality Management System (QMS) that meets stringent regulatory requirements, offering its customers peace of mind in the safety and performance of their devices. “FDA registration is a game-changer for Cortland Biomedical and our customers,” said Tara Yunkunis, Senior Business Development Manager, Cortland Biomedical. “This milestone underscores our dedication to maintaining world-class quality systems and compliance practices. As a contract manufacturer, we can now take a more active role in helping our customers bring innovative medical devices to market faster and with greater confidence.” With extensive expertise in the design and production of advanced biomedical textiles, Cortland Biomedical specializes in creating tailored solutions for a range of applications, including orthopedics, sports medicine, cardiovascular, robotic surgery, general surgery, and others. This expanded capability allows it to now partner with OEMs from initial concept through full-scale manufacturing, providing a seamless, forward-integrated approach to medical device development. For more information about Cortland Biomedical and its expanded capabilities as an FDA-registered contract manufacturer, visit cortlandbiomedical.com or come see the team in booth 2127 at the upcoming MD&M West show in Anaheim, CA. Cortland Biomedical custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical's unique combination of advanced equipment and technology, a seasoned medical textile-specific engineering team, and first-rate R&D capabilities allows it to tackle customers' complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

January 22, 2025 10:00 AM Eastern Standard Time

How Monogram’s (NASDAQ: MGRM) Dynamic Approach To Robotics Could Help Reshape the Future Of Orthopedics

Benzinga

By Meg Flippin Benzinga Robots are becoming increasingly more common in the operating room, but just how automated are they? Monogram Orthopedics Inc. (NASDAQ: MGRM) would argue we have a long way to go before the full potential of robotic technology is fully tapped. The proliferation of robotics and increasing utilization is, at this point, likely a foregone conclusion. After all, some estimates predict that 50% of all knee procedures will be robotic by 2027, up from 11% in 2019. Yet despite the proliferation of AI and fully autonomous robotics in nearly every aspect of daily life, the surgical equipment currently in use for common orthopedic procedures is still reliant on surgeon skill. Monogram’s mBôs robotic technology aims to increase automation and reduce reliance on user skills. As a pioneer in autonomous saw-based cutting, the company has applied decades of robotics experience to amass an extensive portfolio of innovation, including some 23 patent applications in process. The majority of procedures done today combine manual surgery with robotics. The process can still rely heavily on surgeon skill to safely execute the surgery. Monogram’s mBôs aims to minimize direct surgeon contact with the robot mounted tools and hopes to provide surgeons a more autonomous platform for precise surgical bone cuts based on preoperative planning. Monogram’s autonomous robotics platform captured the attention of investment bank Roth Capital Partners, which recently initiated coverage of the company, noting mBôs simplifies surgery as a likely direct challenge to the dominant players in the space. “While orthopedic surgeons remain characteristically conservative, the clinical case for robotics technology is building, and robotics are changing market dynamics,” according to an analyst report compiled by Roth Managing Director Jason Wittes. “We anticipate adoption surpassing 50% over the next five years, and thus see significant strategic value in emerging robotics platforms such as MGRM's mBôs that can challenge MAKO’s dominance.” In addition, Monogram reports its technology pipeline is robust. It plans to introduce mVision in the future, which could enable faster registration and further optimize surgical time compared to competitors. Combination Of Advanced Technologies To Deliver Results Monogram leverages AI and robotics to develop state-of-the-art robots that can assist surgeons with knee reconstruction and, in the future, other procedures like hips, shoulders, ankles and spine. Monogram’s robotic systems aim for precise virtual assessment of laxity values to determine the potential clinical impact of planned resections. Its technology enables surgeons to place implants virtually before cutting to assess the impact of various resections on knee laxity with a target to achieve submillimeter bone cuts. These tools could dramatically simplify the complexity of joint reconstruction in the future. Monogram hopes the mBôs automation could increase throughput and hopes to reduce clinical risk with a planned clinical study to validate. The goal is for the robot to be easy to use and to lower the learning curve for surgeons. With accurate robotics, precision machine cuts can help enable the use of press-fit implants, eliminating the need for cement. Unlike traditional implants, press-fit implants rely on the patient’s bone to hold the implant in place instead of relying on cement. Natural biologic fixation could reduce the risk of the implant becoming loose for younger active patients as the cement breaks down over time. Showing Off The Tech At HQ Monogram’s unique approach to robotics was on display during an analyst meeting and demo day held in 2024 at the company’s cadaver lab and headquarters in Austin, Texas. Monogram executives – including CEO Ben Sexson, Founder and Chief Medical Officer Dr. Douglas Unis, Chief Technology Officer Dr. Kamran Shamaei and Chief Financial Officer Noel Knape – were on hand along with other senior management team members to provide an overview of the company's progress in combining advanced machine vision, AI and next-generation robotics to improve surgeries and patient outcomes. “We were extremely impressed with the management team, including founder Doug Unis, and the successful product Demonstration of the mBôs Precision Robotic Surgical System in a world-class cadaver lab,” said Dallas Salazar, Doctor Group investor. “The hands-free, fully active system demonstrated to us the ease of use and simplicity that was operated by the founder’s 11-year-old daughter giving more confidence of commercialization and acceptance in the orthopedic robotics community once approved. We believe there is clearly a disruptor in this space that is now bringing a product solution architecture to enable patient-optimized orthopedic implants at scale utilizing artificial intelligence and next-generation robotics.” Market Direction The company believes that the future of the market for robotics is bright. With continued robotic adoption driven by patient outcomes and healthcare providers, it believes robotics are likely to become increasingly autonomous. Given the advancements made in AI and robotics, the systems in place today may still be relatively constrained by a reliance on the precision of individual surgeons. The full potential of robotics could be realized across myriad industries. With the anticipated growth in surgical procedures and critical patient and healthcare business outcomes at stake, coupled with a declining number of orthopedic surgeons, automation could be an answer to the growing demand. Monogram aims to introduce an approach to enabling true automated robotic precision that has the potential to transform the way surgeons around the world perform knee replacements and other orthopedic procedures. Featured photo by SOMKID THONGDEE on Shutterstock. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 22, 2025 08:45 AM Eastern Standard Time

Image

News Release

Salignostics Advances Saliva-Based HIV Testing with Successful Clinical Trial in Ethiopia

Salignostics

Salignostics, a leader in saliva-based diagnostic innovation, proudly announces the successful completion of a clinical trial in Ethiopia for its groundbreaking saliva-based HIV rapid test. This major milestone brings Salignostics closer to providing a transformative solution for HIV testing, particularly in areas with limited access to healthcare infrastructure. The trial, conducted in November 2024, evaluated 50 saliva samples from individuals diagnosed with HIV alongside 50 samples from healthy participants. The results demonstrated exceptional accuracy, with sensitivity exceeding 90% and specificity surpassing 98%. These findings underscore the reliability of saliva as a diagnostic medium and highlight its potential to address critical healthcare challenges worldwide. Accurate, accessible HIV testing is vital for early detection and treatment, especially in underserved regions. Salignostics’ saliva-based test eliminates the need for blood draws and specialized equipment, offering a cost-effective and non-invasive alternative that can be deployed in homes, clinics, or community health settings. This innovation not only reduces barriers to testing but also empowers individuals to take control of their health with privacy and convenience. “This successful trial highlights the value of saliva as a diagnostic medium,” said Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics. “By leveraging our technology, we aim to complement existing HIV testing methods and provide a reliable, accessible solution that meets the needs of diverse communities worldwide.” The global HIV diagnostics market is rapidly expanding, driven by increasing demand for decentralized and user-friendly solutions. The market is projected to reach $3.88 billion by 2021, with forecasts of further growth to over $7 billion by 2034 at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2034. Building on its success with saliva-based diagnostics, Salignostics continues to expand its portfolio. The company has a proven track record, including CE, UKCA, and TGA certifications for its Salistick pregnancy test, which has achieved over 500,000 units sold and ordered across markets such as the UK and Israel. Salignostics’ development pipeline also includes applications for oral cancer, respiratory conditions, and sexually transmitted infections, further demonstrating the versatility of saliva as a diagnostic tool. For Salignostics, the successful Ethiopian trial is a significant step forward in transforming global healthcare. By providing accurate and accessible HIV testing, the company is addressing critical gaps in public health while reinforcing its commitment to innovation and quality in diagnostics. About Salignostics Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company’s proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Founded in 2017 in Jerusalem, Salignostics is a global leader in saliva-based diagnostics. The company's proprietary technology has been successfully commercialized, with its Salistick pregnancy test achieving over 500,000 units sold and ordered in markets such as the UK and Israel. Now approved by CE, UKCA, and TGA, Salignostics is actively expanding its portfolio of innovative, user-friendly diagnostic solutions. For more information about Salignostics and its groundbreaking saliva-based diagnostics, visit www.salignostics.com Contact Details Salignostics Guy Krief | Co-founder and Deputy CEO, Salignostics guykrief@salignostics.com Company Website https://www.salignostics.com/

January 21, 2025 05:15 PM Eastern Standard Time

Flash Earns HITRUST Certification, a First in Parking Technology

Flash

Flash, the leading AI-powered parking technology provider, today announced it has achieved HITRUST Certification for its PARCS and Valet solutions, the first and only parking technology provider to earn the distinction. The achievement confirms Flash’s data security practices meet the highest standards trusted by 81 percent of U.S. hospitals and health systems. Flash's HITRUST-certified PARCS and Valet solutions align its security frameworks with those of its healthcare clients and reduce their implementation complexity and risk. The certification also gives assurance to patients, visitors, physicians and staff that their information is safe from the moment they enter the parking facility. “We have a track record of setting new standards in parking," said Flash CEO Dan Sharplin. “Our focus on reimagining the parking experience calls for putting security front and center, within and beyond healthcare. We’re also committed to a great experience for operators and owners, and this certification allows us to carry the technical burden of compliance on their behalf.” Flash PARCS and Valet solutions have earned the trust of the country’s largest medical district and from healthcare systems in major metros nationwide, including Atlanta, Boston, Chicago, Denver, Houston, New York City, Orange County, Phoenix, Pittsburgh and San Diego. Flash’s industry-leading parking technology has also earned designation as a Level 1 Service Provider by the Payment Card Industry (PCI) Data Security Standards (DSS), which it has maintained for 11 consecutive years. Its cloud-based platform can process over 500 million transactions yearly in a secure environment that limits the risk of data loss, disruption, or corruption. Operating entirely in the cloud also allows Flash to manage compliance for operators and owners, pushing security updates and routine system checks required by PCI and HITRUST standards over the air, which become operational within minutes. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use daily with garage, surface lot, event, and valet parking locations—connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

January 21, 2025 10:00 AM Central Standard Time

Forum Health Expands Its Footprint in the DC Metro with a New Integrative Health Clinic Offering Personalized Care

Forum Health

Forum Health, LLC, a nationwide leader in functional and integrative medicine, is excited to announce the opening of its newest clinic in Silver Spring, Maryland. The new location will deliver the same high-quality, patient-centered care that has become synonymous with Forum Health, offering a comprehensive suite of services. Learn more about Forum Health Silver Spring. Phil Hagerman, CEO: “We are thrilled to bring our innovative functional medicine approach to the vibrant Washington, DC suburb of Silver Spring. At Forum Health, we believe in treating the whole person through personalized care and cutting-edge testing and therapies. This new clinic expands our ability to deliver transformative health outcomes to more patients.” Leading the clinic is Dr. Lynese Lawson, renowned functional medicine physician board-certified in anti-aging and regenerative medicine, and Dr. Umza Mian, board-certified physician in Anti-Aging and Regenerative Medicine (A4M). Joining the team is Jared Sharp, NP, an experienced practitioner specializing in plasma therapy, advanced biologics, regenerative therapies, and functional medicine, with five years in primary care and orthopedics. Designed to empower patients to take control of their health through personalized, data-driven treatment plans, Forum Health Silver Spring provides advanced diagnostics, cutting-edge therapies, and integrative solutions to address a wide range of health concerns, including: - Hormonal and Thyroid Health Optimization: Restoring balance through bioidentical hormone replacement therapy and tailored wellness strategies. - Advanced Wellness Strategies: Using cutting-edge treatments to provide maximum success for patients who desire to optimize every aspect of their health. - Cognitive Decline and Alzheimer’s Disease: Comprehensive plans to improve brain health and prevent and reverse cognitive decline using the Bredesen Protocol. - Weight Loss and Metabolic Health: Scientifically backed programs to support sustainable weight loss and improve overall metabolic function. - Chronic Disease Management: Addressing the root causes of complex and undiagnosed conditions to restore vitality such as Lyme disease and mold toxicity. To further enhance care offerings, the clinic is introducing musculoskeletal shockwave therapy, a revolutionary treatment for musculoskeletal pain, designed to stimulate healing and restore mobility, addressing a variety of conditions such as chronic pain, tendonitis, and injuries. To further enhance care offerings, the clinic is introducing multiple regenerative therapies including plasma therapy, advanced biologics, and low intensity shockwave therapy - a pioneering treatment for musculoskeletal pain, designed to stimulate healing and restore mobility, addressing a variety of conditions such as chronic pain, tendonitis, and injuries. Lynese Lawson, DO, ABAARM, IFMCP: “We’re thrilled to bring Forum Health’s transformative wellness approach to Silver Spring and the greater Maryland/D.C. metro. Our focus on personalized care and addressing the root causes of health concerns will empower patients in this community to take charge of their health and achieve lasting well-being.” The Silver Spring clinic will also feature a highly skilled team of medical professionals who blend conventional medicine with natural remedies, lifestyle interventions, and advanced technology. Patients will benefit from a warm, collaborative environment that prioritizes long-term health and wellness. Grand Opening and Appointment Scheduling The Forum Health Silver Spring clinic opened its doors in early December 2024. Appointments can be scheduled here or by calling 703-822-5003. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. integrative Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

January 14, 2025 08:50 AM Eastern Standard Time

Health Care Select Sector SPDR Fund (XLV): Capturing the Growth in Healthcare Consumer Spending

Select Sector SPDR

In the face of rising consumer spending on healthcare, the Health Care Select Sector SPDR Fund ( XLV ) positions itself as a strategic investment vehicle, offering investors a focused approach to the U.S. healthcare sector. Tracking healthcare stocks within the S&P 500 Index, XLV provides broad exposure to key companies leading various sub-sectors such as pharmaceuticals, health insurance, medical devices, and diagnostics. Healthcare Sector Fund: An Overview The healthcare sector continues to benefit from significant growth drivers. These include an increase in chronic diseases, an aging population, and rapid technological advancements. As the sector integrates deeper into the economic landscape, its relevance to consumers and investors alike has solidified, offering a potential opportunity for investment. Highlighting XLV's Holdings The Health Care Select Sector SPDR Fund (XLV) is characterized by its broad holdings, providing a balanced exposure to the healthcare industry. Key holdings* in the fund include: Eli Lilly (LLY) - 12.10% UnitedHealth Group (UNH) - 9.26% Johnson & Johnson (JNJ) - 6.93% AbbVie (ABBV) - 6.25% Merck (MRK) - 5.01% Thermo Fisher Scientific (TMO) - 3.96% Abbott Labs (ABT) - 3.90% Intuitive Surgical (ISRG) - 3.70% Pfizer (PFE) - 2.99% Danaher (DHR) - 2.94% These companies represent a wide spectrum of healthcare, ensuring many industries within the sector are represented. Strategic Appeal of XLV For investors seeking a comprehensive strategy to engage with the healthcare sector, XLV offers a robust solution. By spreading investments across a variety of leading healthcare companies, XLV reduces the risks associated with investing in individual stocks. This approach provides investors with a stable pathway to participate in one of the fastest-growing sectors of the economy. The fund's focus on core healthcare leaders aligns with the ongoing shifts in healthcare delivery models and consumer needs, making it an attractive option for both seasoned investors and newcomers seeking to capitalize on healthcare's growth. As healthcare continues to play an integral role in the global economy, the Health Care Select Sector SPDR Fund (XLV) stands as a practical choice for investors looking to effectively capture the steady increase in consumer spending on healthcare. With its focused holdings and strategic exposure to key industry players, XLV offers a balanced and informed approach to investing in the healthcare sector. For more information on the Health Care Select Sector SPDR Fund (XLV) please visit www.sectorspdrs.com. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 12/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL008109 EXP 3/31/25 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

January 13, 2025 05:00 AM Eastern Standard Time

U.S. Court of Appeals Decision Marks Another Win for CoorsTek in Trademark Litigation

CoorsTek

CoorsTek Bioceramics has secured a decisive win in the U.S. Court of Appeals for the Federal Circuit affirming the company’s right to market and sell its Permallon® Tru* ceramic hip components in the U.S. The recent decision confirms the 2022 U.S. PTO Trademark Trial and Appeal Board (TTAB) cancellation of trademark registrations by Ceramtec GmbH. “Alternative sourcing of these components is necessary to prevent supply shortages for this critical care market,” said Jonathan Coors, CEO of CoorsTek. “The U.S. Court of Appeals decision marks another victory for CoorsTek in this case, but it is ultimately patients across the globe who will benefit.” CoorsTek Bioceramics entered the hip arthroplasty industry in 2013 with its Permallon® Tru technical ceramic material which contains a chromium oxide additive for improved performance, including increased hardness. The pink coloring of products manufactured from Permallon® Tru ceramic is a natural byproduct of the additive. CoorsTek initiated proceedings in 2014 following attempts by Ceramtec to enforce its trademark and trade dress claims to the color pink for its ceramic hip components. In 2022 the TTAB ruled to cancel the trademark registrations, finding the pink color is functional and a natural result of following the teachings in the expired Ceramtec patent on the material. The recent U.S. Court of Appeals decision affirms the cancellation. The 2022 TTAB decision followed a prior CoorsTek victory in the U.S. District Court for the District of Colorado, which was vacated on procedural grounds. Lucian Strong, President, CoorsTek Bioceramics said, “Products manufactured from Permallon® Tru ceramic material demonstrate exceptional mechanical performance and durability. We are pleased to continue offering these products to leading medical device OEMs who have come to rely upon high-performance, high-quality components provided by CoorsTek.” Hip systems incorporating Permallon® Tru hip components been registered for use by customers of CoorsTek Bioceramics in multiple locations across the globe, including the U.S., Korea, China, and the EU. *Formerly marketed as CeraSurf®-p About CoorsTek Bioceramics CoorsTek Bioceramics is dedicated to leading edge manufacturing of technical ceramic implantcomponents for the medical device industry. A wholly owned subsidiary of CoorsTek, Inc.,CoorsTek Bioceramics is backed by over 100 years of technical ceramics expertise. With afocus on ceramic bearing surfaces for total joint arthroplasty, CoorsTek Bioceramics components can also be found in implant devices for neurological, cardiological, spinal, andradiological applications. Since 2005, over six million CoorsTek Bioceramics components havebeen sold and distributed for clinical use. About CoorsTek Founded in 1910, CoorsTek is a leading global manufacturer of technical ceramics. By leveraging expertise in engineering and materials science, CoorsTek provides solutions to complex technical challenges in the semiconductor, medical, automotive, aerospace and other industries. With over 400 proprietary material formulations, vertically integrated systems, and unparalleled process capabilities, CoorsTek partners with its customers to make the world measurably better. Visit www.coorstek.com Contact Details CoorsTek Megan Maguire +1 303-503-2287 mmaguire@coorstek.com Company Website https://www.coorstek.com

January 09, 2025 06:00 AM Mountain Standard Time

Advancing Clinical Studies, Meeting Regulatory Milestones, Strengthening Its Strategic Framework And More: The Past Year For Glucotrack, And What Lies Ahead

Benzinga

By JE Insights, Benzinga Although a manageable disease, diabetes imposes significant hurdles on patients, both in terms of personal care and financial costs. Fundamentally, the required frequency of blood glucose monitoring combined with the broader logistical burdens of supply management (involving items like strips, sensors and insulin) have levied significant disruptions on the overall quality of life for patients and caregivers. Glucotrack, Inc. (NASDAQ: GCTK) aims to radically alter this standard of care. Leveraging its Continuous Blood Glucose Monitor (CBGM), Glucotrack has positioned itself to positively impact the diabetes management industry. Specifically, the market for continuous glucose monitoring (CGM) – which encompasses devices worn on the body daily – may reach a valuation of $16.2 billion by the end of 2024. By 2034, the arena could expand by a compound annual growth rate (CAGR) of 10.3% to hit $16.2 billion. Unlike most other CGM devices, however, Glucotrack’s CBGM offers several distinct benefits, including these advantages: Direct blood glucose measurement: The medical technology specialist’s CBGM utilizes the gold standard of measuring blood glucose instead of interstitial fluid, facilitating more accurate and timely readings with minimal lag. Extended sensor longevity: Glucotrack’s sensors last for three years before requiring replacement, thus helping to reduce expenses. Generally, standard CGM sensors last up to 15 days. No on-body wearables: The company’s fully implantable design eliminates external devices, enhancing comfort, discretion and avoidance of adhesive-related issues. Minimal calibration requirements: Glucotrack says its CBGM requires relatively few calibrations, simplifying the maintenance protocol compared to some CGMs. Reduced lifestyle disruptions: Finally, the CBGM’s “hands-free” approach offers easier integration into daily life. Glucotrack reports that it made great strides in 2024, particularly in the areas of clinical validation and strategic manufacturing partnerships. In addition, the medical device specialist achieved key regulatory and quality milestones in a bid to ensure compliance and readiness for market entry. A Year Of Breakthroughs And Progress Wasting no time when the calendar turned to 2024, Glucotrack hit the ground running from the first quarter. In January, management announced the completion of preclinical studies demonstrating very highly accurate blood glucose monitoring results at 60 days. This test demonstrated the reliability of the CBGM system over an extended period. In the next month, the medical tech firm announced a partnership with Cirtec as the manufacturer of the flagship CBGM. Glucotrack said that over the years, Cirtec has forged a reputation as a leader in the design and manufacturing of implantable medical devices in the fields of neuromodulation, cardiology and drug delivery. By the second quarter, Glucotrack’s commitment to clinical innovation took center stage. Between April and June, the company announced the first reported long-term preclinical study of glucose monitoring in the epidural space. This innovative approach not only demonstrated Glucotrack’s technological versatility but also expanded the potential applications for its CBGM system, further setting it apart from conventional solutions. In June, the company presented key findings at the prestigious American Diabetes Association (ADA) conference. Two poster presentations highlighted the CBGM’s accuracy and sensor longevity. The first underscored the system’s ability to deliver reliable blood glucose readings, while the second demonstrated its potential to last up to three years, far exceeding the lifespan of all existing standard CGM devices. These presentations bolstered Glucotrack’s credibility within the medical community, attracting attention from researchers, clinicians and potential industry partners. Momentum carried into the third quarter with a poster presentation at the Association of Diabetes Care & Education Specialists (ADCES) conference in August. Here, Glucotrack shared market research data showing significant patient interest in its implantable CBGM system. This response affirmed the unmet need for a more convenient and less intrusive solution, strengthening the company’s positioning for future adoption. Capping off the year, Glucotrack began its first-in-human clinical study with the first cohort of participants. This short-term study will further validate the CBGM system, paving the way for more extensive trials in 2025. Additionally, the company expanded its leadership team and board, bringing in experts with decades of experience in CGM technologies and medical device commercialization. These strategic moves are aimed at setting Glucotrack up for continued growth and success in the coming year. Looking Ahead To 2025 As Glucotrack moves into 2025, the company is prepared to accelerate its mission to transform diabetes management. Building on the foundation established in 2024, Glucotrack plans to prioritize clinical validation, regulatory progress and strategic partnerships to bring its CBGM closer to market. The first major milestone on the horizon is the full data readout from the first in-human short-term clinical study initiated in December 2024. This readout will offer the first human-specific validation of the CBGM system’s safety and accuracy, a pivotal step in establishing the technology’s credibility. Additionally, the company intends to launch a long-term feasibility study, which will run for at least one year. This extended evaluation will provide critical insights into the CBGM’s performance over time, bolstering the evidence base needed for regulatory approvals and patient adoption. On the regulatory front, Glucotrack is preparing to meet key FDA requirements by completing the quality and manufacturing activities necessary for investigational devices; the company expects to receive ISO13485 certification in early 2025. These efforts will ensure that the CBGM meets rigorous safety and efficacy standards, paving the way for more advanced clinical trials. Furthermore, the company plans to submit a second long-term feasibility study to the FDA, demonstrating its commitment to a methodical and thorough regulatory pathway. To support its clinical and regulatory efforts, Glucotrack will also focus on expanding its cache of published clinical and scientific evidence. Sharing results through peer-reviewed journals and major conferences will help establish the CBGM as a scientifically credible and groundbreaking solution. This growing body of evidence may also serve to attract strategic partners and financial backers, further accelerating the company’s progress. Finally, the company plans to unveil more details about its commercialization strategy, focusing on how to address patient needs and expand access to this innovative solution. By advancing clinical studies, meeting regulatory milestones and strengthening its strategic framework, Glucotrack has been hard at work setting the stage for a transformative year. With these initiatives, the company believes it is well-positioned to continue its journey toward redefining diabetes care. Featured photo by Silvia on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

January 07, 2025 08:30 AM Eastern Standard Time

Image

1 ... 5 6 7 8 9 ... 209

Back